Assessing Eastman Chemical: Insights From 7 Financial Analysts
Portfolio Pulse from Benzinga Insights
Eastman Chemical (NYSE:EMN) has received mixed reviews from 7 financial analysts over the past quarter, with recent ratings ranging from bullish to indifferent. The average 12-month price target for EMN has been raised to $100.0, up 5.26% from $95.00, with individual targets ranging from $89.00 to $121.00. Analyst actions include both upgrades and downgrades, reflecting changing market dynamics and company performance. Despite a -7.0% decline in revenue growth as of December 31, 2023, Eastman Chemical boasts a strong net margin of 14.05% and excels in ROE and ROA, indicating robust financial management and effective asset utilization.
April 09, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eastman Chemical has seen a diverse range of analyst ratings, with a notable increase in its average 12-month price target. Despite facing revenue growth challenges, the company's strong net margin, ROE, and ROA highlight its financial health and operational efficiency.
The mixed analyst ratings combined with an increase in the average price target suggest a cautiously optimistic outlook for EMN. The company's strong financial indicators, such as net margin, ROE, and ROA, despite a revenue decline, support a potential positive short-term impact on its stock price. The diverse analyst opinions reflect uncertainty, but the overall positive financial health could drive investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100